PTAB Won't Rehear Challenge To Prostate Cancer Drug Patent
The Patent Trial and Appeal Board won't reconsider its decision not to review a patent covering Sanofi's prostate cancer drug Jevtana, saying Tuesday that Neptune Generics LLC's disagreement with the decision...To view the full article, register now.
Already a subscriber? Click here to view full article